Will vaccines appear on the scene of oncology in the near future?

Česká verzia

Authors: V. Vonka
Authors place of work: Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Marek Trněný, CSc.
Published in the journal: Vnitř Lék 2010; 56(7): 739-746
Category: 80th Birthday - Jaroslava Blahoše, MD, DrSc.

Summary

In parallel with the increasing knowledge of the role played by the immune system in the control of tumour growth, the efforts to develop anti‑cancer vaccines intensify. In the present time two highly efficient prophylactic vaccines against the virus‑induced cancers are in use, but a rapid progress in the development of anti‑cancer therapeutic vaccines can also be seen. It is conditioned by an increasing understanding of the biology of the tumor cells and the rapid progress in the field of immunology. Nevertheless, these developments are associated with a number of difficulties, among which the immunosuppressive activities of the tumor cells and the tumor microenvironment are the most important. On the example of chronic myeloid leukemia the author proposes a strategy for the development of a therapeutic cancer vaccine.

Key words:
vaccines – cancer – chronic myeloid leukemia

Zdroje

1. Blumberg BS. Primary and secondary presentation of liver cancer caused by HBV. Front Biosci 2010; 2: 756–763.

2. Vonka V, Hamšíková E. Vaccines against human papillomaviruses – a major breakthrough in cancer prevention. Cent Eur J Public Health 2007; 15: 131–139.

3. Martin D, Gutkind JS. Human tumor‑associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27 (Suppl 2): S31–S42.

4. Šmahel M, Sobotková E, Vonka V et al. DNA vaccines against oncogenic hamster cells trnasformed by HPV16 E6/E7 oncogenes and the activated ras oncoogene. Oncol Rep 1999; 6: 211–215.

5. Fattori E, Aurisiccho L, Zampaglione I et al. ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum Gene Ther 2009; 20: 253–265.

6. Wang H, Wei H, Zhang R et al. Genetically targeted T cells eradicate established breast cancer in syngeneic mice. Clin Cancer Res 2009; 15: 943–950.

7. Su JH, Wu A, Scotney E et al. Immunotherapy for cervical cancer: Research status and clinical potential. Bio Drugs 2010; 24: 109–129.

8. Cid-Arregui A. Therapeutic vaccines against human papillomaviruses and cervical cancer. Open Virol J 2009; 3: 67–83.

9. Ullrich E, Bonmort M, Mignot G et al. Tumor stress, cell death and ensuing immune response. Cell Death Differ 2008; 15: 21–28.

10. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory molecules in antitumor immunity. Immunol Rev 2009; 229: 126–144.

11. Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181–273.

12. Dong H, Strome SE, Salomao DR et al. Tumor associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800.

13. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849–861.

14. Jäger E, Ringhoffer M, Karbach J et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T-cell response: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470–476.

15. Knutson KL, Lu H, Stone B et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006; 177: 1526–1533.

16. Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Oncol 2009; 21: 53–59.

17. Stewart TJ, Abrams SI. How tumors escape mass destruction. Oncogene 2008; 27: 5894–5903.

18. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J Immunother 2009; 32: 1–11.

19. Petrausch U, Poehlein CH, Jensen SM et al. Cancer Immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med 2009; 9: 673–682.

20. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti‑inflammatory and pro‑inflammatory responses. Cancer Biol Ther 2005; 4: 924–933.

21. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor  and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13: 5262–5270.

22. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27–31.

23. Gabrilovich DL, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.

24. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372–383.

25. Mocellin S, Pilati P, Nitti D. Peptide‑based anticancer vaccines. Curr Med Chem 2009; 16: 4779–4796.

26. Němečková Š, Šroller V, Heintz P et al. Experimantal therapy of HPV16 induced-tumors with IL12 expressed by recombinant vaccinia virus in mice. Int J Mol Med 2003; 12: 789–796.

27. Liu MA. Gene‑based vaccines: recent development. Curr Opin Mol Ther 2010; 12: 86–93.

28. De Gruijl TD, van den Eertwegh AJ, Pinedo HM et al. Whole- cell cancer vaccination: from autologous to allogenic tumor and dendritic cell‑based vaccines. Cancer Immunol Immuther 2008; 57: 1569–1577.

29. Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2010; 2: 227–241.

30. Pinilla-Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myeloid leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune response. Blood 2000; 95: 1781–1787.

31. Cathart K., Pinilla-Ibartz J, Korotsvit et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037–1042.

32. Bocchia M, Gentili S, Abruzzese E et al. Effects of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 957–962.

33. Rojas JM, Knight K, Wang I et al. Clinical evaluation of BCR-ABL peptide in chronic myeloid leukemia: results of EPIC study. Leukemia 2007; 21: 2287–2295.

34. Jain N, Reuben JM, Kantarjian H et al. Synthetic tumor-specific breakpoint vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009; 115: 3924–3934.

35. Maslak PG, Dao T, Gomez M et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008; 22: 1613–1616.

36. Takahashi T, Tanala Y, Nieda M et al. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 2003; 27: 595–802.

17. Ossenkoppele GJ, Stam AG, Westers TM et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemia dendritic cells. Leukemia 2003; 17: 1424–1426.

38. Westermann J, Kopp J, van Lessen A et al. Vaccination with autologous non‑irradiated dendritic cells in patients with bcr/abl- chronic myeloid leukemia. Br J Hematol 2007; 137: 297–306.

39. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematological malignancy. Hematology Am Soc Hematol Educ Program 2003: 331–349.

40. Rezvani K, Yong AS, Mielke S et al. Leukemia‑associated antigen-specific T-cell response following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.

41. Li Z, Qiao Y, Liu B et al. Combination of imatinib mesylate with autologous leukocyte derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460–4468.

42. Smith BD, Kasamon YL, Kowalski J et al. K562/GM‑CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010; 16: 338–347.

43. Grünebach F. Mirakaj V, Mirakaj V et al. BCR-ABL is not immunodominant in chronic myeloid leukemia. Cancer Res 2006; 66: 5892–5900.

44. Brauer KM, Werth D, von Schwarzenberg K et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous lekemia cells. Cancer Res 2007; 67: 5489–5497.

45. Caballero OL, ChenYT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014–2021.

46. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T cell response to CML under imatinib treatment. Blood 2008; 111: 5342–5349.

47. Kim PS, Lee PP, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 2008; 4: e1000095.

48. He L, Feng H, Raymond A et al. Dendritic cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother 2001; 50: 31–40.

49. Kislin KL, Marron MT, Li G et al. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti‑tumor activity against a murine BCR-ABL- positive leukemia. FASEB J 2007; 21: 2173–2184.

50. Ling X, Wang Y, Dietrich MF et al. Vaccination with leukemia cells expressing cell-surface‑associated GM‑CSF blocks leukemia induction in immunocompetent mice. Oncogene 2006; 25: 4483–4490.

51. Deeb D, Gao X, Jiang H et al. Vaccination with leukemia-loaded dendritic cells eradicates residual diseases and prevents relapse. J Exp Ther Oncol 2006; 5: 183–193.

52. Lučanský V, Sobotková E, Tachezy R et al. DNA vaccination against bcr-abl-positive cells in mice. Int J Oncol 2009; 35: 941–951.

53. Hrušková V, Morávková A, Babiarová K et al. Bcr-Abl fusion sequences do not induce immune response in mice when administered in mouse polyomavirus based virus‑like particles. Int J Oncol 2009; 35: 1247–1256.

54. Ramquist T, Dalianis T. Immunotherapeutic polyoma and human papillomavirus‑like particles. Immunotherapy 2009; 1: 303–312.

55. Petráčková M, Sobotková E, Dušková M et al. Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors. Neoplasma 2009; 56: 194–201.

56. Sobotková E, Dušková M, Tachezy R et al. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncol Rep 2009; 21: 793–799.

57. Radich JP, Dai H, Mao M et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794–2799.

58. Diaz-Bianco E, Bruns I, Neumann F et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007; 21: 494–504.

59. Song JH, Kim HJ, Lee CH et al. Identification of gene signatures for molecular classification in human leukemia cells. Int J Oncol 2008; 29: 57–94.

60. Zou L, Wu Y, Pei L et al. Identification of leukemia- associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res 2005; 29: 1387–1391.

61. Fontana S, Alessandro R, Barranca M et al. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res 2007; 6: 4330–4342.

62. Ferrari G, Pastorelli R, Buchi F et al. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistence. J Proteome Res 2007; 6: 367–375.